Correspondence and requests for reprints should be addressed to Catherine Igartua, B.S., University of Chicago, Human Genetics, 920 E. 58th St., CLSC 431F, Chicago, IL 60637. E-mail: cigartua@uchicago.edu

Ann Am Thorac Soc Vol 13, Supplement 1, pp S100–S101, Mar 2016

Internet address: www.atsjournals.org

Genetic Variation in Surfactant Protein-A2 Results in Altered Regulation of Eosinophil Activities and Enhanced Eosinophilia in Patients with Asthma

Julie G. Ledford[1,2], Kenneth J. Addison[1,2], Dave Francisco[1,2], Matthew W. Foster[1], Dennis R. Voelker[3], Loretta G. Que[1], and Monica Kraft[1,2]

[1]Department of Medicine, Duke University Medical Center, Durham, North Carolina; [2]Department of Medicine, University of Arizona, Tucson, Arizona; and [3]Department of Medicine, National Jewish Health, Denver, Colorado

Humans express a repertoire of single amino acid genetic variant proteins for surfactant protein (SP)-A1 and SP-A2 that may be associated with certain lung physiology and disease. We have previously shown that SP-A mediates eosinophil degranulation and that certain allelic variants of SP-A2 are dysfunctional in asthma. We therefore hypothesized that variation in SP-A2 at position Gln(Q)223Lys(K) leads to altered regulation of eosinophil activities and that patients with asthma who harbor the minor allele may demonstrate enhanced eosinophilia. SP-A was extracted from the lavage of patients with alveolar proteinosis and genotyped for the SP-A2 223Q/K locus. Genotyped SP-A was incubated with eosinophils *in vitro* to assess regulation of eosinophil activity. Humanized SP-A transgenic mice were created that represent single allelic variant changes in SP-A2 protein, designated SP-A2 223Q and SP-A2 223K. Humanized mice were challenged in an allergic model to determine the effect of SP-A genetic variation during allergic inflammation. We discovered that SP-A2 223Q inhibits eosinophil degranulation and leads to reduced viability of eosinophils in culture conditions. In contrast, SP-A2 223K is unable to attenuate eosinophil degranulation and has no effect on eosinophil viability. Humanized SP-A2 223Q mice have significantly reduced mucus production in an allergic model compared with SP-A$^{-/-}$ mice, whereas mice expressing SP-A2 223K were not different from mice that are devoid of SP-A. Additionally, from genotyped samples obtained from subjects with mild to moderate asthma, we discovered that subjects with asthma harboring one or more copies of the minor allele (223K) had a greater percentage of eosinophils in their bronchoalveolar lavage and serum. These studies suggest that genetic variation in SP-A2 at position SP-A2 Gln223Lys is an important mediator of eosinophil activities, which may lead to a more severe asthma phenotype.

Author disclosures are available with the text of this abstract at www.atsjournals.org.

(Received in original form August 13, 2015; accepted in final form August 18, 2015)

Correspondence and requests for reprints should be addressed to Julie G. Ledford, University of Arizona, Medicine, 1657 East Helen Street, Keating Building/Bio5, Tucson, AZ 85721. E-mail: jagledford@gmail.com

Ann Am Thorac Soc Vol 13, Supplement 1, p S101, Mar 2016

Internet address: www.atsjournals.org

Antisense MicroRNA Therapy of Airway Remodeling in House Dust Mite–sensitized Mice

Sabrina Ramelli[1], Jared Milligan McLendon[1], Andrew P. Ferretti[2], Jason Fewell[3], Robert Barrington[2], and William T. Gerthoffer[4]

Departments of [1]Biochemistry and Molecular Biology and [2]Microbiology and Immunology, College of Medicine, University of South Alabama, Mobile, Alabama; [3]Preclinical Development, Celsion Corporation, Huntsville, Alabama; and [4]College of Medicine, University of South Alabama, Mobile, Alabama

There is compelling need for mechanistically novel antiinflammatory and antiremodeling drugs for therapy of severe asthma. Our goal is to develop systemically administered agents that provide long-acting suppression and reversal of lung inflammation, mucosal metaplasia, and airway structural cell remodeling. To inhibit remodeling, microRNA (miR)-145 was targeted because it is a key regulator of structural cell differentiation and inflammation. An antisense, locked nucleic acid/DNA oligonucleotide complementary to nucleotides 2–16 of hsa-miR-145–5p (anti–miR-145) was delivered to the lungs via a novel lipid nanoparticle administered intravenously. After sensitization with house dust mite (HDM), 2 cohorts of 10 mice were treated with dextrose or anti–miR-145 nanoparticles (2 mg/kg, intravenously, on Days 13, 15, and 17). A third cohort of control mice was not sensitized to HDM and was not treated with anti–miR-145. Bronchoalveolar lavage (BAL) was performed on Day 18, and lungs were fixed with formalin. There was significant eosinophilia of the BAL fluid after challenge with HDM, and increased CD68 immunostaining of tissue sections, which verified the effectiveness of HDM challenge. Airway and vascular wall remodeling and increased mucin-producing cells were observed in HDM-challenged animals. Mice treated with anti–miR-145 showed reduced BAL eosinophilia, reduced obstructive airway remodeling, reduced mucosal metaplasia, and reduced CD68 immunoreactivity. Anti–miR-145 delivered intravenously distributed to most cells in the lung parenchyma, as shown by *in situ* hybridization. Antagonizing the function of miR-145 in the lung significantly reduces obstructive remodeling in a short-term HDM mouse model of asthma. These results also establish the biodistribution and efficacy of anti–miR-145 delivered via the blood compartment, which bypasses obstructed airways that can limit distribution and efficacy of inhaled antisense oligonucleotides.

Author disclosures are available with the text of this article at www.atsjournals.org.

(Received in original form July 8, 2015; accepted in final form July 14, 2015)

Correspondence and requests for reprints should be addressed to William T. Gerthoffer, Ph.D., University of South Alabama College of Medicine, Biochemistry and Molecular Biology, 307 North University Boulevard, Mobile, AL 36688-0002. E-mail: wgerthoffer@southalabama.edu